Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Trading Up 1.1% – Should You Buy?

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) shares traded up 1.1% during trading on Friday . The company traded as high as $27.76 and last traded at $27.54. 5,140 shares were traded during mid-day trading, an increase of 147% from the average session volume of 2,082 shares. The stock had previously closed at $27.25.

Amplify Weight Loss Drug & Treatment ETF Price Performance

The company has a market capitalization of $5.51 million, a PE ratio of 24.31 and a beta of 0.37. The company has a 50 day moving average of $25.79 and a two-hundred day moving average of $25.19.

Institutional Trading of Amplify Weight Loss Drug & Treatment ETF

A hedge fund recently raised its stake in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC lifted its holdings in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,891 shares of the company’s stock after buying an additional 1,215 shares during the quarter. Jane Street Group LLC owned approximately 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 as of its most recent SEC filing.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.